Insilico Medicine Signs AI Drug-Discovery Deal With SK Biopharmaceuticals Worth Up to $2.5 Billion
The AI-driven biotech will run target-to-candidate discovery for neuroimmune disorders, while its Korean partner takes the molecules through late-stage development - Insilico's largest potential deal in Asia-Pacific to date.
media age.house
AI-driven drug-discovery company Insilico Medicine has entered a research collaboration with SK Biopharmaceuticals to develop treatments for neuroimmune disorders of the central nervous system, the companies announced on June 21, 2026. The partnership carries a total potential value exceeding $2.5 billion — the largest Insilico has secured with an Asia-Pacific partner to date.
The Deal
Under the agreement, Insilico will apply its Pharma.AI platform to target validation, generative chemistry, and molecule optimization. SK Biopharmaceuticals will take the resulting candidates through late-stage development and commercialization.
| Term | Figure |
|---|---|
| Upfront and near-term milestones | up to $18 million |
| Total potential deal value | > $2.5 billion |
| Additional consideration | development, regulatory, and commercial milestones, plus single-digit royalties on net sales |
| Therapeutic area | neuroinflammatory, neurodegenerative, and rare neurological conditions |
The structure is typical of AI-discovery partnerships: a modest upfront payment, with the headline figure contingent on milestones that only pay out if candidates advance through trials, win approval, and reach the market.
Why It Matters
The collaboration pushes SK Biopharmaceuticals beyond epilepsy — the area behind its U.S. drug XCOPRI® (cenobamate) — into a broader set of central-nervous-system targets.
“This collaboration represents an important milestone in expanding our growth beyond epilepsy into new CNS therapeutic areas,” said Donghoon Lee, President and CEO of SK Biopharmaceuticals.
For Insilico, the deal is further validation of a discovery model built on speed. The company says its platform can reach preclinical-candidate nomination in 12–18 months, against a traditional industry timeline of 2.5–4 years.
“By uniting Insilico’s AI-driven target-to-candidate engine with SK Biopharmaceuticals’ deep CNS mastery, we aim to unlock breakthrough therapies,” said Dr. Alex Zhavoronkov, Founder, Co-CEO, and Chief Business Officer of Insilico Medicine.
The Companies
Insilico Medicine (HKEX: 3696) is a clinical-stage, AI-driven drug-discovery company. It says it has nominated 31 preclinical candidates since 2021, of which 13 have received investigational new drug (IND) approval. Its work sits at the intersection of machine learning and biology that has drawn growing attention from the longevity field — founder Alex Zhavoronkov is also known for research on AI-based aging biomarkers.
SK Biopharmaceuticals is a global biotech focused on CNS disorders and the first Korean pharmaceutical company to independently develop and commercialize a novel drug in the United States. It operates through its U.S. subsidiary, SK Life Science, Inc., and has been expanding into radiopharmaceutical therapies and targeted protein degradation.
Details: The announcement was published by Insilico Medicine on June 21, 2026. Financial terms, timelines, and figures in this article are drawn from that release and have not been independently verified. Deal values described as “potential” or “up to” are contingent on milestones and may not be fully realized.
Disclaimer
This content is for informational and educational purposes only and is not medical advice. Always consult a qualified healthcare professional before making changes to your health.
